Skip to main content
Premium Trial:

Request an Annual Quote

Snipping HIV Out

Researchers from Temple University have received the go-ahead to test their gene-editing approach for treating HIV, the Philadelphia Inquirer reports.

It adds that researchers led by Kamel Khalili, a microbiologist and virologist there, first used CRISPR to remove HIV that has integrated into host DNA in a lab in 2014, and subsequently tested the approach in other human cells in the lab as well as in mouse models and, in 2019, in macaque monkeys. Khalili and his co-founded Excision BioTherapeutics about five years ago and it has since raised $60 million to funds its clinical trials, the Inquirer adds.

However, the Inquirer notes that the approach make not be able to fully remove all HIV copies, raising the question of level is good enough. "That's the question in the [research] field: Do we need to completely eliminate every viral copy to achieve the cure?" Tricia Burdo, a cell and molecular biologist at Temple, tells it. "We don't know yet."

Khalili suspects, it adds, that removing or deactivating most copies would likely lead to a functional cure, and he adds that the treatment, if found to be safe and effective, could be offered as a one-time treatment.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.